Scopolamine Market Size

  • Report ID: 3312
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Scopolamine Market Size

Scopolamine Market size was valued at USD 511.78 billion in 2024 and is expected to reach USD 1001.5 billion by 2037, expanding at around 5.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of scopolamine is assessed at USD 556.1 billion.
 

The growth of the market can be attributed to the growing number of surgeries across the world. The number of surgeries performed worldwide every year was estimated to be over 300 million as of 2020. The increasing application of scopolamine motion sickness is estimated to drive market growth. The increasing awareness of people regarding the benefits of scopolamine is projected to fuel market growth in the coming years.

The number of people traveling around the world is expected to boost market growth. Many travelers suffer from motion sickness which causes vomiting and nausea during the journey. Scopolamine helps to prevent the feeling of nausea by blocking the nerves with an anticholinergic effect. The increasing use in people suffering from vertigo which cause severe headache and then vomiting is estimated to boost the market growth in the coming years. More than 40% of Americans suffer from vertigo once during their life as per the estimations in 2021.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3312
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of scopolamine is assessed at USD 556.1 billion.

The scopolamine market size was valued at USD 511.78 billion in 2024 and is expected to reach USD 1001.5 billion by 2037, expanding at around 5.3% CAGR during the forecast period i.e., between 2025-2037. Increasing number of surgical procedures, the number of people suffering from digestive disorders, and psychological disorders will boost the market growth.

Asia Pacific industry is estimated to dominate majority revenue share of 32% by 2037, attributed to increasing number of people suffering from ophthalmic disorders and the increasing number of surgeries in the elderly population.

The major players in the market are Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co. Ltd, Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc., GlaxoSmithKline plc, Aktivax, Inc., Southwest Research Institute, Perrigo Company plc, Novartis International AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample